Table 1

Baseline demographic and clinical characteristics for randomised and treated patients

Abatacept+MTX (n=27)Placebo+MTX (n=23)
Age (years)51.7±11.252.5±11.5
Female, n (%)16 (59.3)16 (69.6)
Caucasian, n (%)26 (96.3)19 (82.6)
Duration of RA (months)25.7±18.028.2±17.0
Tender joints, n12.9±7.113.3±7.2
Swollen joints, n11.3±6.68.5±4.1
Patient global assessment, VAS 100 mm50.9±24.756.6±24.4
Physician global assessment, VAS 100 mm51.5±18.757.4±15.1
Positive RF status, n (%)*15 (55.6)19 (82.6)
Positive anti-CCP2 status, n (%)*13 (48.1)17 (73.9)
DAS28 (CRP)5.3±1.15.3±0.9
CRP (mg/l)13.6±17.416.6±16.8
SDAI (CRP)35.8±16.134.9±10.8
Concomitant medications at baseline, n (%)
 MTX23 (100)27 (100)
 MTX dose, mean±SD mg/week16.9±4.617.3±4.2
 Oral and/or injectable corticosteroids19 (70.4)14 (60.9)
 Low dose oral corticosteroids16 (59.3)12 (52.2)
 Oral dose of corticosteroids, mean±SD3.9±3.513.0±3.72
 NSAIDs22 (81.5)20 (87.0)
  • Values are means±SD unless stated otherwise.

  • *Per the inclusion criteria, if patients were not RF or anti-CCP2 positive, they had to have radiographic evidence of erosion.

  • CCP, cyclic citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simplified Disease Activity Index; VAS, visual analogue scale.